Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387686 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 367
- Enrollment target
NCT00387686 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 367 participants.
The verdict
NCT00387686, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 367 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered at the fracture site via percutaneous injection, in combination with standard of care, accelerates fracture union and return to normal function in subjects who have a closed diaphyseal tibial fracture when compared to standard of care alone.
Interventions
- DRUG rhBMP-2/CPM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387686
The ClinicalTrials.gov registry entry for NCT00387686 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhBMP-2/CPM is the first listed.
NCT00387686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387686 about?
NCT00387686 is a clinical study titled "A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures". The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered at the fracture site via percutaneous injection, in combination with standard of care, accelerates fracture union and return to normal function in subjects who have a closed diaphyseal tibial fracture ...
What is the current status of trial NCT00387686?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 367 participants. The study started on 2006-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00387686?
The interventions under investigation include: rhBMP-2/CPM (DRUG).
Who is sponsoring clinical trial NCT00387686?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.